Immune Checkpoint Blockade in Melanoma – Earlier is Better?
Administering checkpoint inhibition before surgery, known as neoadjuvant therapy, shows promise in treating bulky yet resectable melanomas, and researchers are investigating its potential in various other cancer types. This approach boasts a considerable success in high pathologic response rate, a...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Vilnius University Press
2024-09-01
|
| Series: | Acta Medica Lituanica |
| Subjects: | |
| Online Access: | https://www.journals.vu.lt/AML/article/view/32871 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832593379707322368 |
|---|---|
| author | Vincas Urbonas Audrius Dulskas Edita Baltruškevičienė Daiva Dabkevičienė |
| author_facet | Vincas Urbonas Audrius Dulskas Edita Baltruškevičienė Daiva Dabkevičienė |
| author_sort | Vincas Urbonas |
| collection | DOAJ |
| description |
Administering checkpoint inhibition before surgery, known as neoadjuvant therapy, shows promise in treating bulky yet resectable melanomas, and researchers are investigating its potential in various other cancer types. This approach boasts a considerable success in high pathologic response rate, a factor directly linked to survival rates. The routine availability of biopsies presents a distinct chance to comprehend treatment responses. Neoadjuvant ICIs offer advantages like T cell expansion, treatment assessment through surgical specimens, and potential tumor size reduction for better surgical outcomes. However, further research is needed to optimize patient selection and treatment protocols.
Erratum note
The abstract have been updated to reflect the correct information following a typographical error during typesetting. We apologize for any inconvenience caused by these errors. Below, you will find the corrected version. Corrections were made on 2024-09-01.
Updated Abstract
Administering checkpoint inhibition before surgery, known as neoadjuvant therapy, shows promise in treating bulky yet resectable melanomas, and researchers are investigating its potential in various other cancer types. This approach boasts a considerable success in high pathologic response rate, a factor directly linked to survival rates. The routine availability of biopsies presents a distinct chance to comprehend treatment responses. Neoadjuvant ICIs offer advantages like T cell expansion, treatment assessment through surgical specimens, and potential tumor size reduction for better surgical outcomes. However, further research is needed to optimize patient selection and treatment protocols.
|
| format | Article |
| id | doaj-art-24851ed7f73a40a980c342fd97a5f8bf |
| institution | Kabale University |
| issn | 1392-0138 2029-4174 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Vilnius University Press |
| record_format | Article |
| series | Acta Medica Lituanica |
| spelling | doaj-art-24851ed7f73a40a980c342fd97a5f8bf2025-01-20T18:07:53ZengVilnius University PressActa Medica Lituanica1392-01382029-41742024-09-0131110.15388/Amed.2024.31.1.16Immune Checkpoint Blockade in Melanoma – Earlier is Better?Vincas Urbonas0Audrius Dulskas1Edita Baltruškevičienė2Daiva Dabkevičienė3National Cancer Institute, Laboratory of Clinical Oncology, Vilnius, LithuaniaNational Cancer Institute, Laboratory of Clinical Oncology, Vilnius, LithuaniaNational Cancer Institute, Laboratory of Clinical Oncology, Vilnius, LithuaniaBiobank, National Cancer Institute, Vilnius, Lithuania Administering checkpoint inhibition before surgery, known as neoadjuvant therapy, shows promise in treating bulky yet resectable melanomas, and researchers are investigating its potential in various other cancer types. This approach boasts a considerable success in high pathologic response rate, a factor directly linked to survival rates. The routine availability of biopsies presents a distinct chance to comprehend treatment responses. Neoadjuvant ICIs offer advantages like T cell expansion, treatment assessment through surgical specimens, and potential tumor size reduction for better surgical outcomes. However, further research is needed to optimize patient selection and treatment protocols. Erratum note The abstract have been updated to reflect the correct information following a typographical error during typesetting. We apologize for any inconvenience caused by these errors. Below, you will find the corrected version. Corrections were made on 2024-09-01. Updated Abstract Administering checkpoint inhibition before surgery, known as neoadjuvant therapy, shows promise in treating bulky yet resectable melanomas, and researchers are investigating its potential in various other cancer types. This approach boasts a considerable success in high pathologic response rate, a factor directly linked to survival rates. The routine availability of biopsies presents a distinct chance to comprehend treatment responses. Neoadjuvant ICIs offer advantages like T cell expansion, treatment assessment through surgical specimens, and potential tumor size reduction for better surgical outcomes. However, further research is needed to optimize patient selection and treatment protocols. https://www.journals.vu.lt/AML/article/view/32871Melanomaneoadjuvant treatmentimmunotherapy |
| spellingShingle | Vincas Urbonas Audrius Dulskas Edita Baltruškevičienė Daiva Dabkevičienė Immune Checkpoint Blockade in Melanoma – Earlier is Better? Acta Medica Lituanica Melanoma neoadjuvant treatment immunotherapy |
| title | Immune Checkpoint Blockade in Melanoma – Earlier is Better? |
| title_full | Immune Checkpoint Blockade in Melanoma – Earlier is Better? |
| title_fullStr | Immune Checkpoint Blockade in Melanoma – Earlier is Better? |
| title_full_unstemmed | Immune Checkpoint Blockade in Melanoma – Earlier is Better? |
| title_short | Immune Checkpoint Blockade in Melanoma – Earlier is Better? |
| title_sort | immune checkpoint blockade in melanoma earlier is better |
| topic | Melanoma neoadjuvant treatment immunotherapy |
| url | https://www.journals.vu.lt/AML/article/view/32871 |
| work_keys_str_mv | AT vincasurbonas immunecheckpointblockadeinmelanomaearlierisbetter AT audriusdulskas immunecheckpointblockadeinmelanomaearlierisbetter AT editabaltruskeviciene immunecheckpointblockadeinmelanomaearlierisbetter AT daivadabkeviciene immunecheckpointblockadeinmelanomaearlierisbetter |